RAC 2.20% $1.78 race oncology ltd

Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-73

  1. 19,269 Posts.
    lightbulb Created with Sketch. 6359
    Yes that is the hope, but I really can't say. The abstract was submitted some time ago (it needs to be peer reviewed by the ASH conference committee) and it is entirely possible that Dan's work was not finished before the abstract went in. If it is complete before December then we may see something in the presentation. We will just have to wait.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.